PT - JOURNAL ARTICLE AU - Maassen, W.T.K. AU - Johansson, L.F. AU - Charbon, B. AU - Hendriksen, D. AU - van den Hoek, S. AU - Slofstra, M.K. AU - Mulder, R. AU - Meems-Veldhuis, M.T. AU - Sietsma, R. AU - Lemmink, H.H. AU - van Diemen, C.C. AU - van Gijn, M.E. AU - Swertz, M.A. AU - van der Velde, K.J. TI - MOLGENIS VIP: an open-source and modular pipeline for high-throughput and integrated DNA variant analysis AID - 10.1101/2024.04.11.24305656 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.11.24305656 4099 - http://medrxiv.org/content/early/2024/04/26/2024.04.11.24305656.short 4100 - http://medrxiv.org/content/early/2024/04/26/2024.04.11.24305656.full AB - In silico variant interpretation pipelines have become an integral part of genetics research and genome diagnostics. However, challenges remain for automated variant interpretation and candidate shortlisting. Their reliability is affected by variability in input data caused due the use of differing sequencing platforms, erroneous nomenclature and changing experimental conditions. Similarly, differences in predictive algorithms can result in discordant results. Finally, scalability is essential to accommodate large amounts of input data, such as in whole genome sequencing (WGS). To accelerate causal variant detection and innovation in genome diagnostics and research, we developed the MOLGENIS Variant Interpretation Pipeline (VIP). VIP is a flexible open-source computational pipeline that generates interactive reports of variants in whole exome sequencing (WES) and WGS data for expert interpretation. VIP can process short- and long-read data from different platforms and offers tools for increased sensitivity: a configurable decision-tree, filters based on human phenotype ontology (HPO) and gene inheritance that can be used to pinpoint disease-causing variants or finetune a query for specific variants. Here, alongside presenting VIP, we provide a step-by-step protocol for how to use VIP to annotate, classify and filter genetic variants of patients with a rare disease that has a suspected genetic cause. Finally, we demonstrate how VIP performs using 25,664 previously classified variants from the data sharing initiative of the Vereniging van Klinisch Genetische Laboratoriumdiagnostiek (VKGL), a cohort of 18 diagnosed patients from routine diagnostics and a cohort of 41 patients with a rare disease (RD) who were not diagnosed in routine diagnostics but were diagnosed using novel omics approaches within the EU-wide project to solve rare diseases (EU-Solve-RD). VIP requires bioinformatic knowledge to configure, but once configured, any diagnostic professional can perform an analysis within 5 hours.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received funding from the EU projects Solve-RD, EJP-RD and CINECA (H2020 779257, H2020 825575, H2020 825775, respectively) and NWO grant numbers 917.164.455 and 184.034.019.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Prof. H.P.H. Kremer MD PhD, chair of Medical Ethics Review Board, University Medical Center Groningen, declares that the submission entitled: MOLGENIS VIP: an open-source and modular pipeline for high-throughput and integrated DNA variant analysis. by Maassen et al, fulfils all the requirements for patient anonymity and is in agreement with regulations of our University Hospital for publication of patient data. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe previously classified variants from the VKGL can be downloaded from https://vkgl.molgeniscloud.org/. The routine diagnostics cohort contains patient data from patients within the UMCG and can therefore only be shared upon request. The Solve-RD research cohort is available as a dataset (EGAD50000000390) in the European Genome-Phenome Archive and can be accessed by sending a data access request to the data access committee of the EU-Solve-RD project.